One of the key drivers of growth in the extracorporeal membrane oxygenation (ECMO) market is the increasing use of ECMO in the treatment of COVID-19 patients. The pandemic has highlighted the importance of ECMO in the treatment of critically ill patients and has driven demand for the technology worldwide. Many hospitals have upgraded their ECMO systems and expanded their ECMO programmes to meet the growing demand.

According to GlobalData, the top revenue-grossing sub-segments for ECMO include blood pumps, integrated units, and oxygenators, which together account for approximately 80% of the total market revenue. Getinge is a market leader, leading in integrated units, which is the second largest sub-segment overall. Furthermore, Getinge is leading in every region except the North-East region of the US. In addition to growing demand for ECMO systems, the market is also being driven by advancements in ECMO technology, including the development of portable ECMO systems, improved oxygenators, and new anticoagulant technologies. These advancements are improving patient outcomes and making ECMO more accessible and cost-effective for patients and healthcare providers alike.

Due to these drivers, in January 2023, the ECMO market is thriving, with growing demand for technologies, new products and service offerings, and continued advancements in ECMO technology. As the market continues to evolve, ECMO will likely become an increasingly important part of the healthcare landscape, providing life-saving treatment options for critically ill patients.